Aerosol administration of peptide-based drugs plays an important role in the treatment of pulmonary and systemic diseases and the unique cellular properties of airway epithelium offers a great potential to deliver new compounds. As the relative contributions from the large airways to the alveolar space are importantto the local and systemic availability, the sites and mechanism of uptake and transport of different target compounds have to be characterized. Among the different respiratory cells, the ciliated epithelial cells of the larger and smaller airways and the type I and type II pneumocytes are the key players in pulmonary drug transport.With their diverse cellular characteristics, each of these cell types displays a unique uptake possibility. Next to the knowledge of these cellular aspects, the nature of aerosolized drugs, characteristics of delivery systems and the depositional and pulmonary clearance mechanisms display major targets to optimize pulmonary drug delivery.Based on the growing knowledge on pulmonary cell biology and pathophysiology due to modern methods of molecular biology, the future characterization of pulmonary drug transport pathways can lead to new strategies in aerosol drug therapy. r
INTRODUCTION
In addition to their prominent role in the regulation of the airway tone and the production of airway lining £uid, the respiratory epithelial cells display an important barrier between higher organisms and their environment which can be used for pharmacological interventions. In this respect, the large surface area of approximately 70^140 m 2 in adult human lungs can be e⁄ciently used for the aerosolic administration of a large variety of drugs. The topical administration of non-peptide and peptidomimetic drugs already plays an important role in the treatment of various pulmonary and systemic diseases and on the basis of new knowledge on distinct transport systems (1,2) aerosolic drug delivery may be optimized and is reaching a higher bioavailability.
TOPICAL AND SYSTEMIC DRUGS AND COMPOUNDS
A general distinction between topical and systemic compounds has to be made: for the aerosolic administration of topical, respiratory drugs, a large number of substances already exists encompassing di¡erent classes of asthma(3), antimicrobial (4) and pulmonary antihypertensive therapeutics (Table 1) (5) .
Also, a large number of reports on the pulmonary delivery of systemic drugs exist. In this respect, di¡erent non-peptide and peptide-based drugs such as insulin (6^8), human growth hormone (9) and oxytocin have been reported to reach the systemic circulation following aerosol administration (Table 2) .
With regard to the most socio-economically most important systemic compound, insulin, recent studies have addressed the optimization of the delivery process. Using human monocomponent insulin in lyophilized dextran starch microspheres, a bioavailability of 30% was achieved after administration to the nasal cavity of rats with peak insulin concentrations within 7^10 min and a maximal decrease in glucose blood concentration after 20^30 min.
As the relative contributions from the large airways to the alveolar space are important to the local and systemic availability, the sites and mechanism of uptake of the di¡erent target compounds have to be characterized. Among the di¡erent respiratory cells, the ciliated epithelial cells of the larger and smaller airways and the type I and type II pneumocytes are the key players in pulmonary drug transport.With their diverse cellular characteristics, each of these cell types displays unique uptake characteristics.
CELLULAR ASPECTS OF PULMONARY DRUG TRANSPORT
The transepithelial transport of compounds along the respiratory epithelium from the upper airways with nasopharynx, trachea and large bronchi to the lower respiratory tract with small bronchioles and alveoli is characterized by large quantitative di¡erences. In this respect, the transport in the upper airways is limited by a smaller surface area and lower regional blood £ow. Also, the upper airways possess a high ¢ltering capacity and remove 70^90% of pressurized particles. In contrast, the smaller airways and alveolar space account for more than 95% of the lung's total surface area (10) . Also, this compartment is directly connected to the systemic circulation via the pulmonary circulation.
There are two major cell types found in the alveolar epithelium: type I and type II pneumocytes. Whereas type I cells have a very thin cell body with long membranous extensions, occupying an area of about 95% of the alveolar surface(11), the type II pneumocytes are characterized by a more cuboidal morphology and cover about 5% of the total alveolar surface (12, 13) . Studies on the subcellular morphology of type I cells revealed the presence of endocytotic vesicles which may function as carriers in the absorption processes of larger proteins such as insulin (5.7 kDa) (14, 15) . Although type II pneumocytes express a variety of transport proteins (1, 2) , it is generally accepted that their main functions are the production of surfactant proteins and the di¡erentiation into type I cells after epithelial barrier injuries.
The pulmonary blood^gas barrier consists of a thick and a thin side, which are composed of the alveolar epithelium, the capillary endothelium, and the intervening extracellular matrix (basement membranes of the two cell layers) (16) .
Out of the two cell types involved in the blood^gas barrier, the type I cells display most likely the rate-limiting step concerning the uptake of compounds into the pulmonary circulation as previous studies reported a 10 3 times lower permeability for substances such as sucrose in comparison to endothelial cells (17) . This is based on the di¡erence in pore size between alveolar cells (0.61 nm) and endothelial cells (4^5.8 nm) (18)and the tight junctions depth which is 0.26170.023 mm (signi¢cantly) higher than the tight junctions depth of the capillary endothelial cells (0.16670.011 mm) (19) .
In contrast to these conditions at the blood^gas barrier, three other di¡erent types of tight junctions have been identi¢ed for extra-and intrapulmonary airways (20) . Most importantly, they di¡er in the degree of luminal ¢bril interconnections which are sparsely interconnected in type I, more densely interconnected in type II and most densely interconnected in type III tight junctions.While the type I is almost exclusively found between extrapulmonary airway ciliated cells, the type II is primarily present in smaller airways and between Clara cells and the type III between mucous cells (20) with a secretory cycle-associated change in permeability.
This dependence upon the secretory cycle, which is leakier when the mucous cells are in a state of active secretion has also been reported for other cell types such as mammary gland epithelial cells (21, 22) . It is most likely 
AEROSOL ADMINISTRATION AND DEPOSITION
There are two primary modes of pulmonary aerosol administration: nasal and oral inhalation. As the nasal inhalation is limited by anatomical features such as a narrower airway lumen, oral inhalation of compounds is generally preferred. In this respect, previous studies demonstrated (23,24) a far better oral inhalative administration of 5 mm diameter particles with a concentration loss of only 20% in comparison to 85% by nasal administration.
The three principal mechanisms which lead to pulmonary deposition are inertial impaction, sedimentation and di¡usion. The inertial impaction occurs during the passage through the oropharynx and large conducting airways if the particles possess a certain mass and velocity. Inertial impaction can be partially in£uenced by hyperventilation and does not occur when particles have a diameter below 3 mm. These particles are subject to sedimentation by gravitational force which occurs in smaller airways and is in£uenced by breath-holding. From a range below 0.5^1 mm, particles are deposited by di¡u-sion which is based on the Brownian motion (25^27).
There are di¡erent parameters with a crucial in£u-ence on the site, extent and e⁄cacy of speci¢c deposition of aerosolic drugs. Next to morphological aspects and ventilatory parameters (26, 28) , the aspect of particle/droplet size and geometry is most important.Within this area, there are numerous factors with an in£uence on the deposition, including particle size (diameter), density, electrical charge, hygroscopy, or shape (i.e. ¢bers) (25, 29, 30) . Also, deposition is in£uenced by the particle source which can be a solution, powder or suspension (26, 27) . In this respect, it was demonstrated that solution-based aerosols were characterized by 2-mm massmedian aerodynamic diameter (MMAD) particles whereas suspension-based aerosols displayed 4 -mm MMAD particles (31). The particle size is commonly expressed as the aerodynamic diameter, which is a variable depending on the shape, density and size of the object. If aerosols contain di¡erent particles, the size distribution is usually characterized by the MMAD. A maximal alveolar deposition is reached with particle sizes of 3 mm and an increase of the MMAD leads to an inertial impactionbased shift in deposition in larger airways. In this respect, the oropharyngeal deposition of an 8 -mm particle has a probability of about 50%, whereas it reaches approximately 100% for a 16 -mm particle (32) .
Also, hygroscopic characteristics can in£uence the deposition and due to the high levels of relative humidity, reaching about 44 mg/cm 3 in the alveolar lumen, particles may be subject to changes in size. In this respect, depending on water content and airway tonicity, hypertonic particles can increase in size by hygroscopic growth with a consecutive change in deposition towards larger airways (33) .
Major ventilatory parameters with impact on the particle deposition are breath pattern, £ow rates and tidal volume and there can be large inter-and intraindividual variations in these parameters. As an example, breathholding for 5^10 s on completion of inhalation, a low £ow rate (less than 20 l/min), and an increase in the inhaled volume can lead to an increase in particle deposition, especially for particles with a diameter around 0.5 mm which are subject to sedimentary deposition (34^36). In contrast, low £ow rates of 15 l/min can lead to an increase in large conductance airway deposition of 43 mm particles due to inertial impaction (37) and also, rapid inhalation together with a high respiratory rate increases inertial impaction of particles in the large airways (38) .
DELIVERY DEVICES
Although there is a large number of devices (39, 40) which can be used to generate particles (Table 3) , the most common systems are nebulizers, metered dose inhalers (MDIs) and dry powder inhalers (PDIs). The currently available standard inhalation devices generally produce aerosols which are heterodisperse in size. Although monodisperse particle-sized aerosols are better speci¢cally targeted to the lower airways, the production of these is largely limited by complex and expensive generation processes such as vibrating ori¢ce, spinning disc method or electrostatic precipitation (40, 41) .
PULMONARYCLEARANCE OF AEROSOL-ADMINISTERED DRUGS
There are two major clearance pathways for substances which are transported across the respiratory epithelium: the mucociliary system and alveolar macrophages. Whereas the mucociliary system is bound to the larger airways, the macrophages are found both in the alveolar space and along larger and smaller airways.
Mucociliary clearance
The mucociliary clearance displays an integrative function of beating cilia and lining £uid with the two main purposes of trapping and transporting airborne particles.
Ciliated epithelial cells cover 30^65% of the airway epithelial cells in the human respiratory tract, and each ciliated cell houses about 200 cilia of 5^6 mm length at a density of 6^8 mm -2 (42) . Parallel to the decrease of mucociliary transport activity as the airways become smaller, the distribution of ciliary epithelial cells changes and the percentage decreases from 53% in the trachea to 45% in the ¢rst airway generation, to 15% in the ¢fth airway generation (43) .
The lining £uid is composed of the periciliary £uid, a lubricating layer surrounding the cilia, the viscous layer of mucus and the gel layer.Transport through these layers is functionally distinct as they consist of di¡erent components such as soluble and gel-forming mucins which can be altered in their composition in disease (44, 45) .
The mucociliary clearance rate, which can be used as an outcome measure for potential therapeutic agents, is about10 mm/min in the trachea of normal individuals (46) . The clearance rate can be examined indirectly as ciliary beat frequency (47) or directly as the rate of removal of marker substances.The ciliary beat frequency and mucociliary transport are generally well correlated (48) and the beat frequency can be assessed in vivo and in vitro (49^51).
ALVEOLAR CLEARANCE
Aerosol particles which have been deposited in the alveolar space and terminal airway units can be subject to absorptive or non-absorptive removal processes. Whereas the nature of non-absorptive transport processes of particles from the terminal airway units to the airways with mucociliary clearance activity has not been fully elucidated so far, the absorptive removal processes involves uptake by macrophages and epithelial cells (52) . The adhesion of airborne particles to alveolar macrophages is mediated through electrostatic interaction or receptor mediation and particles are then internalized through surface cavitation, or vacuole and pseudopod formation (53) . Depending on the nature of the particles, internalization is followed by further metabolization or digestion by peptidases in case of proteins (52, 54) .
Activated macrophages may then secrete a variety of cyto-and chemokines and migrate to the ciliated airway epithelium for transport via mucociliary clearance or penetrate through the respiratory epithelium into the interstitial tissue (13) .
The internalization of airborne particles depends on the particle size and composition of coating material. Both features can be used to selectively control drug uptake by alveolar macrophages. While particles of 3 mm diameter are far better internalized than particles with 6 mm, a diameter of less than 0.26 mm prevents from macrophageal phagocytosis (55^57).
The diversity of the clearing processes can be illustrated by the deposition of radio-labeled aluminosilicate particles of diameter sizes 1.2 and 3.9 mm, which was shown to be a triphasic process with half-lives of approximately 1, 20 and 4300 days. These phases were suggested to correspond to the processes of mucociliary clearance, alveolar macrophages clearance and alveolar epithelium penetration (58) .
CONCLUSION
Pulmonary administration of drugs plays an important role in the treatment of various respiratory and systemic diseases and displays an attractive area of future drug development. The e¡ects of an aerosol-based drug are dependent on a variety of factors: starting from the nat- ure of the compounds, cellular aspects, characteristics of delivery systems and aerosol administration to deposition in pulmonary clearance mechanisms (Fig.1) , multiple ways to manipulate drug delivery exist.
An optimal delivery system would speci¢cally deposit the drug at its pulmonary target region, independent of ventilatory or pathophysiological parameters. To optimize current delivery systems, future studies addressing the unique molecular, biochemical, and physiological characteristics of various respiratory regions have to be carried out applying modern techniques of molecular biology (59) , morphology (60, 61) and physiology (62, 63) .
